CA2188228C - Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders - Google Patents

Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders Download PDF

Info

Publication number
CA2188228C
CA2188228C CA002188228A CA2188228A CA2188228C CA 2188228 C CA2188228 C CA 2188228C CA 002188228 A CA002188228 A CA 002188228A CA 2188228 A CA2188228 A CA 2188228A CA 2188228 C CA2188228 C CA 2188228C
Authority
CA
Canada
Prior art keywords
compound
formula
cancer
phenyl
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002188228A
Other languages
English (en)
French (fr)
Other versions
CA2188228A1 (en
Inventor
Wilfried Schwab
Jorg Czech
Klaus Boslett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CA2188228A1 publication Critical patent/CA2188228A1/en
Application granted granted Critical
Publication of CA2188228C publication Critical patent/CA2188228C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002188228A 1995-10-25 1996-10-18 Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders Expired - Fee Related CA2188228C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19539638A DE19539638A1 (de) 1995-10-25 1995-10-25 Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19539638.3 1995-10-25

Publications (2)

Publication Number Publication Date
CA2188228A1 CA2188228A1 (en) 1997-04-26
CA2188228C true CA2188228C (en) 2008-08-12

Family

ID=7775689

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002188228A Expired - Fee Related CA2188228C (en) 1995-10-25 1996-10-18 Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders

Country Status (10)

Country Link
US (2) US5886033A (https=)
EP (1) EP0769296B1 (https=)
JP (1) JP3996658B2 (https=)
AT (1) ATE202704T1 (https=)
CA (1) CA2188228C (https=)
DE (2) DE19539638A1 (https=)
DK (1) DK0769296T3 (https=)
ES (1) ES2160197T3 (https=)
GR (1) GR3036754T3 (https=)
PT (1) PT769296E (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP1012150A4 (en) * 1997-05-19 2002-05-29 Sugen Inc HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
EP0933633A1 (en) * 1997-12-11 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Process for obtaining L-dihydroorotic acid and use thereof
DE19857009A1 (de) * 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7247736B2 (en) * 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
MXPA06014754A (es) 2004-06-17 2007-06-22 Infinity Pharmaceuticals Inc Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
DE102006014165A1 (de) * 2006-03-24 2007-09-27 Schebo Biotech Ag Neue Isooxazol-Derivate und deren Verwendungen
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US11096934B2 (en) * 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
CN111423374B (zh) * 2020-05-18 2023-03-21 合肥工业大学 一种二氢吡唑磺酰胺类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
ES2102367T3 (es) * 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
NZ244814A (en) * 1991-10-23 1994-06-27 Hoechst Ag N-phenyl-2-cyano-3-hydroxycrotonamide derivatives and pharmaceutical compositions
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease

Also Published As

Publication number Publication date
ES2160197T3 (es) 2001-11-01
US6020372A (en) 2000-02-01
JP3996658B2 (ja) 2007-10-24
DK0769296T3 (da) 2001-10-22
CA2188228A1 (en) 1997-04-26
GR3036754T3 (en) 2001-12-31
EP0769296B1 (de) 2001-07-04
EP0769296A1 (de) 1997-04-23
DE59607208D1 (de) 2001-08-09
ATE202704T1 (de) 2001-07-15
US5886033A (en) 1999-03-23
PT769296E (pt) 2001-11-30
JPH09165336A (ja) 1997-06-24
DE19539638A1 (de) 1997-04-30

Similar Documents

Publication Publication Date Title
CA2188228C (en) Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders
Chen et al. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
KR20110031370A (ko) 염산 ｉｃｏｔｉｎｉｂ, 합성, 결정형, 약학적 조성물 및 이의 사용
WO2020221006A1 (zh) 一种bet蛋白抑制剂、其制备方法及用途
Madni et al. Synthesis, crystal structure, anti-HIV, and antiproliferative activity of new pyrazolylthiazole derivatives
BR112015003778B1 (pt) Profármaco de tenofovir, composição farmacêutica, e seus usos
CN104010501B (zh) 含src同源区2蛋白酪胺酸磷酸酶-1增效剂及其治疗方法
SK281318B6 (sk) Amidy kyseliny hydroxyalkylidénkyanoctovej, farmaceutický prostriedok obsahujúci tieto zlúčeniny a ich použitie
JP2014528453A (ja) Ｒａｓアンタゴニストによる悪性および非悪性疾患の治療
Nicely et al. One-pot two-step catalytic synthesis of 6-amino-2-pyridone-3, 5-dicarbonitriles enabling anti-cancer bioactivity
CN111410618A (zh) 具有己糖激酶2抑制活性的化合物及用途
WO2010135170A2 (en) Nitrile derivatives and their pharmaceutical use and compositions
CN106977472B (zh) 苯并异硒唑酮修饰亚硝脲类化合物合成及其应用
CN111943906B (zh) 脒类衍生物、及其制法和药物组合物与用途
CN105949149A (zh) 用于治疗或预防乳腺癌的化合物
WO2018189679A1 (en) Isoindoline derivatives for use as ampk activators
RU2712169C2 (ru) Новые полиморфные формы икотиниба фосфата и их применения
CN114031523B (zh) 一种组蛋白去乙酰化酶与微管双靶标抑制剂的合成方法与应用
AU778825B2 (en) (Z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
JP2018508495A (ja) スニチニブのプロドラッグ及び医薬組成物
Purandara et al. Crystal structure of (E)-4-methyl-N-{2-[2-(4-nitrobenzylidene) hydrazin-1-yl]-2-oxoethyl} benzenesulfonamide N, N-dimethylformamide monosolvate
Huo et al. Discovery of novel tubulin CBSI (R)-9k from the indanone scaffold for the treatment of colorectal cancer
AU2011274194A1 (en) Phenyl nitrone compounds containing stilbene segment and use thereof
KR102547925B1 (ko) 암 치료를 위한 치료제로서의 4-옥소-n-(4-히드록시페닐)레틴아미드 유도체
TWI596098B (zh) 埃克替尼馬來酸鹽的晶型及其用途

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141020